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Abstract
Background Metastasis is the main cause of mortality in can-
cer patients. Two major routes of cancer cell spread are cur-
rently being recognized: dissemination via blood vessels (he-
matogenous spread) and dissemination via the lymphatic sys-
tem (lymphogenous spread). Here, our current knowledge on
the role of both blood and lymphatic vessels in cancer cell
metastasis is summarized. In addition, I will discuss why can-
cer cells select one or both of the two routes to disseminate and
I will provide a short description of the passive and active
models of intravasation. Finally, lymphatic vessel density
(LVD), blood vessel density (BVD), interstitial fluid pressure
(IFP) and tumor hypoxia, as well as regional lymph node
metastasis and the recently discovered primo vascular system
(PVS) will be highlighted as important factors influencing
tumor cell motility and spread and, ultimately, clinical
outcome.
Conclusions Lymphangiogenesis and angiogenesis are im-
portant phenomena involved in the spread of cancer cells
and they are associated with a poor prognosis. It is anticipated
that new discoveries and advancing knowledge on these phe-
nomena will allow an improvement in the treatment of cancer
patients.
Keywords Angiogenesis . Lymphangiogenesis . Lymph
nodes .Metastasis
1 Introduction
It has firmly been established now that high mortality rates in
cancer patients are not only associated with the occurrence of
primary tumors but, even more profoundly, with the occurrence
of metastases [1–3]. This notion implies that cancer-related
death may not just be caused by distortion of the primary af-
fected organs, but also by the distortion of organs at secondary
sites, which jointly affect the whole organism. To initiate me-
tastasis, a solid tumor that develops at a primary site may spread
using existing routes that are related to normal body functions.
During progression from an in situ tumor, aggressive malignan-
cies may disseminate either via blood vessels (hematogenous
spread after neovascularization) or via the lymphatic system
(lymphogenous spread after lymphangiogenesis) [4]. Other
ways throughwhich tumor cells may spread include local tissue
invasion and direct seeding into body cavities. Which way
tumor cells choose to spread depends on the site of tumor
initiation, the aggressiveness of the tumor cells, extrinsic sig-
nals and intrinsic tumor micro-environmental conditions in-
cluding direct cell-cell and cell-matrix interactions within a
tumor niche and the presence of paracrine factors mediating
the formation of new vessels [5]. It has been found that solid
tumors frequently induce angiogenesis and lymphangiogenesis.
Blood and lymphatic vessels, however, offer diametrically dif-
ferent conditions for the migration and survival of tumor cells.
These conditions are closely related to the distinct functions and
structural features of these two systems [6].
2 The functions and structures of blood
and lymphatic vessels
The main function of blood vessels is to transport oxygenated
blood, to exchange oxygen, carbon dioxide, water and mineral
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salts between blood and tissues and to regulate the pressure of
the flow in the closed system powered by the heart. The lym-
phatic system, on the other hand, begins in peripheral tissues
with blind-ended capillaries and has an open, semicircular
layout. Lymph flows unidirectionally from the peripheral tis-
sues to the blood. It does not carry oxygen or essential nutri-
ents. Its primary function is to absorb extravasated protein-
rich fluids, lipids, macromolecules and immunocompetent
cells from the interstitial spaces within tissues. After resorp-
tion from the initial ducts (lymphatic capillaries and then pre-
collectors), lymph is transported to larger vessels (lymphatic
collectors and trunks) and flows back into the bloodstream
mainly via the left lymphatic duct (thoracic duct). Normal
functioning lymphatic vessels thus maintain plasma volume,
prevent increases in tissue pressure and allow easy passage of
leukocytes, thereby playing an important role in the proper
functioning of the immune system and the immune surveil-
lance of the whole body [4, 7–9].
Although blood and lymphatic vessels share a common em-
bryological origin, they differ significantly. A first essential dif-
ference is the anatomy of lymphatic and blood vessels. Initial
and terminal lymphatic capillaries are 10–60μm in diameter and
are lined with a layer of lymphatic endothelial cells (LECs) [10].
Blood capillaries are approximately 5–20 μm in diameter and
have a uniform, compact layer of endothelium. Lymphatic cap-
illaries, unlike blood capillaries, have an incomplete discontinu-
ous basal lamina, or no basal lamina at all, and lack pericytes and
smooth muscle cells [4, 8, 10, 11]. An important feature of
lymphatic capillaries is the size of their lumen, which is three-
fold wider than that of blood capillaries. Moreover, lymphatic
capillaries are unique in that they have reticular, elastic and
collagen fibers (anchoring filaments), which bind LECs to the
extracellular matrix (ECM), a property that is vital to a proper
lymph flow. The fibers stretch to open the lymphatic lumen
(intracellular space) when the volume of the interstitial fluid
increases, thus producing hydrostatic pressure. After this, the
interstitial fluid flows into the lymphatic system causing the
capillaries to dilate rather than to collapse [4, 7, 10–12]. This
is a major feature of lymph absorption. The lymphatic collectors
and trunks differ, however, structurally form lymphatic capil-
laries and are histologically similar to veins. They have a thin,
three-layered coat and valves at the jugulosubclavian junction,
which prevents blood reflux to lymphatic ducts as also retro-
grade lymph flow [8, 10, 13]. Normal blood vessels also contain
three layers. The innermost layer (tunica intima) consists of a
single layer of endothelial cells surrounded by connective tissue
called the internal elastic lamina. The middle layer (tunica
media) is built up of a basement membrane and smooth muscle
cells surrounded by the external elastic lamina. The outermost
layer (tunica adventitia) consist of connective tissue containing
nerves that innervate the vessel [14]. Pathological veins that are
formed as a result of tumor neovascularization differ significant-
ly from normal veins. They are characterized by a chaotic
structure in which endothelial cells do not adhere tightly to each
other but, instead, form protrusions towards the lumen of the
vessel. Also the pericytes adhere only loosely to the endotheli-
um. The basal lamina is thinner than in normal vessels and has
many fenestrations, which makes the vessels permeable. The
diameter of the vessels may vary and blood clots can be formed,
which may result in local differences in blood pressure.
Increases in blood pressure and a high permeability of the ves-
sels may result in the appearance of exudates, which prohibit the
intravasation of cells. A chaotic organization of the vessel net-
works with numerous blind-ended vessels may lead to blood
stasis, or even backflow [15, 16].
3 A passive or active model of tumor cell
dissemination?
Taking the above considerations into account, it appears that the
lymphatic vessel pathway provides a better and safer route for
cancer cell dissemination than the blood vessel pathway. The
composition of the lymph fluid is almost identical to that of the
interstitial tissue fluids, which promotes the survival of migrat-
ing tumor cells. Moreover, the discontinuous structure of the
lymph capillary elements, a low lymph flow, a minimalized
shear stress and a high concentration of hyaluronic acid, which
plays an important role in cell protection and survival, give the
lymphatic system an advantage over the bloodstream, in which
mechanical forces and the toxicity of pure serummay negative-
ly affect circulating tumor cells [7, 17]. Nevertheless, before an
unequivocal claim can be made as to which route of dissemi-
nation is more effective, two questions need to be answered.
The first one deals with the energy that metastasizing cells
require for migration, i.e., whether it is more energy-efficient
for cells to actively move to secondary sites or be shed passive-
ly. The second question is whether it is more proficient, from
the cell’s point of view, to choose the hematogenous or the
lymphatic pathway for the effective formation of distant mi-
cro-metastases. Lymphatic vessels are relatively leaky com-
pared to blood vessels and, as such, are considered essential
for tumor cell spread. The structure of blood vessels would,
under normal circumstances, force tumor cells to spend more
energy during intra- and especially extravasation. In the tumor
neovasculature, however, many abnormalities can be found that
actually facilitate tumor cell migration, including disorganized
wall structures, endothelial fenestrations and a thin or even non-
existing basement membrane [18]. The fragile new blood ves-
sels that vascularize primary tumors are, to a certain extent,
comparable to leaky lymphatic capillaries that lack a continu-
ous basement membrane and contain many open junctions and
pores. This open blood vessel structure suggests that tumor
intravasation may be a passive process. However, it is well
documented that CD73, an enzyme converting AMP to aden-
osine, is actively involved in vascular permeabilization. And
398 R. Paduch
although the ATP metabolism differs in blood and lymphatic
vessels, it has been found that CD73 also plays an important
role in normal lymphocyte migration into lymph nodes [19].
This enzyme may be considered as a major factor in the metas-
tasis of tumor cells. Initially, tumor cells grow in their primary
niche, but when the tumor reaches a diameter of about 1 mm, it
invades its microenvironment and collapses the newly formed
tumor blood vessels. Their fragile non-linear/disordered struc-
ture gives way under the pressure of the tumor mass, enabling
passive entry of tumor cells into the vessel’s lumen and, subse-
quently, metastasis [20]. On the other hand, it has been shown
that invasive tumor cells may detach form their primary masses
and enter tumor-associated absorbing lymphatic (TAAL) ves-
sels through intra-endothelial channels (1.8–2.1 μm in diame-
ter), thus taking a passive route into the lymphatic circulation
[21]. To simplify this model, tumor cells may be washed out
from the tumormass and, with the tide of tissue fluid, be pushed
into lymphatic drainage canals, thereby initiating invasion. The
passive model of intravasation is supported by the finding that
most shed cells are non-vital and non-clonogenic. This means
that the only cells that can survive in vessels (i.e., withstand the
mechanical stresses and the attack of immune cells) and form
metastases are tumor stem cells and cells that express a meta-
static phenotype. However, such an argument implies the ac-
ceptance of an active mechanism of metastasis [21–23]. Other
arguments in favor of an involvement of active mechanisms in
the initial steps of metastasis include the accumulation of mu-
tations, changes in the expression of adhesion molecules, the
presence of chemokine gradients, expression of the urokinase
plasminogen activator (uPA) followed by activation of metal-
loproteinases (MMPs), and the supportive role of stromal cells
and cancer-associated fibroblasts, CAFs [24]. It is believed that
alterations in the primary tumor microenvironment/niche in-
duce tumor cells to migrate towards blood or lymphatic vessels.
Active migration and entry into the vessels may also be facili-
tated by changes in the organization of the cytoskeleton as well
as the acquisition of a metastatic phenotype through epithelial-
mesenchymal transition (EMT) [23].
Despite many reports in the literature on this subject, there is
currently no unequivocal answer to the question which condi-
tions determine the choice of an active or a passive route of
migration by tumor cells. It seems that, depending on the type
of tumor, the stage of its development and/or themetastatic target
organ, tumor cells may select either one or both of these routes.
4 The role of epithelial-mesenchymal transition
in tumor cell metastasis
Besides the acquisition of specific genomic changes by tumor
cells that enable their growth and survival, epithelial-
mesenchymal t rans i t ion (EMT) and the reverse
mesenchymal-epithelial transition (MET) are generally
considered as some of the most fundamental processes under-
lying cancer cell dissemination. EMT is usually reported as
being essential for the initial stages of malignant transforma-
tion and tumor development at the primary site, whereas MET
is believed to be pivotal for the later, metastatic stages and for
the formation of secondary tumors at distant sites [25]. Tumor
cells undergo Btype III EMT ,^ which differs from Btype II
EMT^ that occurs during inflammation or fibrosis and Btype
I EMT ,^ which takes place under normal physiological con-
ditions such as wound healing [26–28]. During EMT tumor
cells acquire a mesenchymal, migratory and invasive pheno-
type by losing their intercellular junctions (i.e., adherens junc-
tions, tight junctions, desmosomal junctions and also, partial-
ly, gap junctions), typical molecular markers (E-cadherin,
cytokeratins), cytoskeletal organization (changes in microtu-
bules, actin filaments, β-filamin or talin), apical/basolateral
polarity and, finally, contact inhibition [27, 29–32]. At their
primary site, tumor cells receive EMT promoting signals from
activated stroma, while at metastatic sites such signals are
weak or absent. Under the latter circumstances, metastatic
tumor cells convert to an epithelial phenotype via MET. This
process is also believed to support tumor-normal cell interac-
tions at distant, metastatic sites, and to be facilitated by the
stimulatory activity of the target organ parenchyma that in-
duces the re-expression of E-cadherin. As a consequence, con-
nections can be formed between neoplastic and normal cells.
Such connections are very important for tumor cell survival
within the new microenvironment [32]. On the basis of direct
and indirect, paracrine stimulations, tumor cells may enter a
state of dormancy at the metastatic target site. Dormant cells
are characterized by a low metabolic activity, a suppressed
anoikis associated with the formation of cell heterotypic E-
cadherin, and a resistance to cytostatics due to activation of
the receptor tyrosine kinase ErbB4 and induction of the PI3K-
Akt pathway [25, 33–35]. Obviously, this is a simplified mod-
el of EMT-MET, and there are other factors that significantly
promote not only EMT-MET, but also lymphangiogenesis and
angiogenesis. Among them, the most important ones are α-
SMA, whose increased expression by myofibroblasts has
been associated with a high expression of N-cadherin, a
LYVE-1-positive vessel count, and increased expression of
VEGF, stromal cell-derived factor 1 (SDF-1) also known as
C-X-C motif chemokine 12 (CXCL12), insulin-like growth
factor-2 (IGF-2), hypoxia-inducible factor-1α (HIF-1α),
transforming growth factorβ (TGF-β) and hepatocyte growth
factor (HGF) [30, 36–39]. In addition, immune cells such as
macrophages, myeloid-derived suppressor cells (MDSCs),
mast cells and neutrophils may contribute to EMT/MET tran-
sitions and the formation of new vessels through the produc-
tion of cytokines, growth factors or proteases [30]. On the
other hand, there are also molecules that may inhibit tumor
angiogenesis, lymphangiogenesis and invasion. One such
molecule is KAI-1/CD82, which belongs to the tetraspanin
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family of proteins and is considered to be a metastasis sup-
pressor. This molecule is localized on the cell membrane and
interacts with integrins and chemokines responsible for the
adhesion, signaling and mobility of cells. Decreased levels
of KAI-1/CD82 have been linked to limited cancer cell inva-
siveness and the suppression of metastatic cell growth mainly
through inhibition of β-catenin-mediated EMT [40, 41].
Generally, molecules that are involved in EMT/MET transi-
tions can be classified as EMT inducers (upstream cytokines
and growth factors or receptors that initiate transition), EMT
regulators (downstream transcription factors controlling the
transition process) and EMT effectors (molecules that cause
cell phenotype changes and endow cells with an invasive
character) [32, 42].
Although EMT and MET are widely recognized as being
essential for tumor cell metastasis, they may proceed differ-
ently in different cancers due to diverse characteristics of the
respective blood and lymphatic vessel systems. It has e.g.
been shown that prostate and breast cancers isolated form
sentinel lymph nodes exhibit an increased invasive potential
without any upregulation of mesenchymal markers [43, 44].
This finding confirms the concept that although mesenchymal
transition contributes to the successful metastasis of tumor
cells, lymph node dissemination does not per se require
EMT [45]. This notion may be explained by the fact that the
structure of the lymphatic system does not force mesenchymal
cells to increase their invasive phenotype. Moreover, EMT
facilitates intravasation, whereas cells leaving the vessels
(extravasation) do not require this process [46]. Therefore, it
may be concluded that in contrast to blood vessel dissemina-
tion, successful lymphatic migration may not require EMT. As
such, EMT does not always appropriately imply the invasion
of tumor cells and, although crucial, it is only one of the
possible mechanisms underlying tumor cell metastasis.
5 The role of the extracellular matrix in tumor cell
metastasis
The tumor stroma is composed of non-cellular components of
the extracellular matrix (ECM) such as proteins, glycoproteins,
proteoglycans and polysaccharides endowing complex physi-
cal and biological properties to the stroma, as well as immune
cells, endothelial cells and fibroblasts (CAFs) that participate in
the early stages of tumor cell dissemination [47, 48]. The ECM,
besides its structural and biomechanical features, can also func-
tion as a repository for active components, such as growth
factors, which are stored and released during alteration or re-
modeling of its composition. Some of the most important con-
stituents of the ECM are laminins, which have a significant
impact on cellular dynamics, and collagens, which are the ma-
jor structural components of the matrix [49–51].
Reorganization of these and other matrix constituents during
cancer development results in deregulation of the ECM and
disruption of its integrity and architecture, thereby promoting
epithelial cell transformation and tumor cell progression [48].
Deregulated ECM dynamics are closely related to the expres-
sion and activity of ECM enzymes including MMPs,
heparanases, 6-O-sulfatases, cysteine cathepsins, urokinase
and the serine protease plasmin [52, 53]. This deregulation
leads to essential changes in ECM properties, which not only
may induce tumor cell motility, but may also affect tumor
micro-environmental stromal cells such as CAFs, immune cells
and mesenchymal stem cells (MSCs) [54–57].
It has been found that released or plasma fibronectins play
an important role in tumor cell adhesion, migration, invasion
and survival by activating integrins via the MAPK/ERK path-
way [58]. Other ECM components and receptors, including
heparan sulfate proteoglycans and CD44, may facilitate the
growth and motility of tumor cells [59–61]. An abnormal
ECM has also been found to participate in the induction of
angiogenesis and lymphangiogenesis during tumor progres-
sion. It has been reported that fragments of type IV and type
XVIII ECM collagens, including endostatin, tumstatin,
canstatin, arresten and hexastatin, strongly influence angiogen-
esis, either directly or indirectly by modulating the VEGF level
[62]. Theymay also modify lumen entrapment involved in tube
formation during angiogenesis. [63, 64]. The role of the ECM
in lymph vessel formation is as yet poorly recognized, but it has
been shown that the ECM receptor integrin α9β1 may be in-
volved in the induction of tumor lymphangiogenesis [65, 66].
Similarly, low molecular weight hyaluronian (LMW-HA) has
been found to promote lymphangiogenesis via interactions with
its lymphatic vessel endothelial hyaluronian receptor 1 (LYVE-
1), which leads to the induction of LEC proliferation and tube
formation [67]. Recently, it has also been found that MT1-
MMP-mediated proMMP-2 activation and the expression of
ECM1 soluble protein and EMILIN1, an elastic microfibryl-
associated protein, are closely linked to lymphangiogenesis and
tumor invasion [68–70]. Taken together, it may be concluded
that changes in biochemical and biomechanical properties of
the ECM represent important factors affecting tumor cell be-
havior during metastasis.
6 How do tumor cells choose between blood
and lymphatic vessels for dissemination?
If tumor cells can use passive and active mechanisms of
intravasation, the question arises what the basis is of dissem-
ination via blood and lymphatic vessels. It has already been
reported that carcinomas and melanomas are more likely to
form lymph node metastases than sarcomas [46]. It is unclear,
however, why, when or where the decision about the route of
intravasation is made. Some hypotheses on this matter have
already been put forward and all of them appear to be equally
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probable. The most obvious factors that may be involved in
this process are the physical/mechanical conditions and the
genetic or epigenetic programs that are innate to tumor cells.
Also, the role of factors that attract tumor cells towards blood or
lymphatic vessels should not be ignored. Among them are in-
flammatory and host hematopoietic precursors, but also soluble
factors such as chemokines, growth factors and soluble recep-
tors [71]. They not only affect the metastatic phenotype of
tumor cells, but also in cases where due to various reasons
(e.g. receptor mismatch, difficulties with EMT, a migration
mode that makes it difficult to penetrate the blood wall barrier)
tumor cells are unable to cross blood vessels, they direct them
into the peri-tumoral lymphatic system (metachronous
seeding), which provides a safer and easier way for the cells
to intravasate and disseminate. As an example, it has been
reported that bradykinin may act as a signal that attracts glioma
cells to blood vessels [72]. Subsequently, these tumor cells may
establish so-called satellite lymph node metastases, which dis-
seminate metastatic cells via the thoracic duct. Some authors
claim that lymph nodes select tumor cells, enabling those with a
high enough malignant phenotype to disseminate further. They
explain ipso facto the differences in malignancy between pri-
mary tumor cells and metastatic tumor cells [46]. Following
this idea, it seems obvious that inhibition of lymph node me-
tastasis should inhibit hematogenous spread. Experimental data
show, however, that this is not always the case.Moreover, it has
been reported that distant metastases can be formed despite a
lack of metastatic cells in sentinel and distant lymph nodes.
This, in turn, may confirm direct dispersal of tumor cells into
blood vessels. There is also a model which proposes that tumor
cells may stay for some time in a non-metastatic state. This state
lasts until the cells are activated and recruited to disseminate
simultaneously via blood and lymphatic vessels [46]. This hy-
pothesis may explain the quick andmassive metastasis which is
characteristic for some cancers.
Tumor cells may disseminate via blood or lymphatic vessels,
but do they show a Bpredilection^ for one route of migration
over the other? Such predilection may depend on various fac-
tors that are specific for the tumor cells, as well as for their
microenvironment and the newly formed vessels. In addition,
specific molecular signaling pathways may play a major role.
Differences in gene expression between the lymphatic and
blood endothelium may constitute one of the major factors that
is decisive for the route of dissemination that tumor cells
choose. Blood endothelial cells (BECs) typically express
CD44, ICAM1, Tie-2/Ang-1 VEGFR-1 and -2, Neutropilin-1
receptors for VEGF-A, -C and -D, and secrete IL-6/8 and
MCP-1. On the other hand, lymphatic endothelial cells express
c-Met/HGF, Tie-2/Ang-1/2, IGF-Rs/IGF-1/2, FGF-Rs/FGF-2,
Podoplanin, LYVE-1 and VEGFR-2 and -3, receptors for
VEGF-C and -D [73–75]. The role of these factors is widely
accepted now, despite controversies on the role of VEGF-D in
lymphangiogenesis and tumor cell dissemination via lymphatic
vessels in some cancers, such as ovarian and breast cancers
[76–79]. VEGF-D has been reported to act as a factor that
induces both intra- and peri-tumoral lymphatic vessel develop-
ment, but not necessarily lymph node metastasis [80, 81].
Gene expression profiles may not only differentiate the
properties of the two cell types involved (i.e., BECs and
LECs), but also the physiological functions of blood and lym-
phatic vessels and their potential to be selected by tumor cells
as a route for metastasis [74]. On the other hand, selection
pressure can also be exerted on tumor cells through the ex-
pression of different receptors and signaling molecules by the
lymphatic or blood endothelium, which allows cells to trans-
migrate via the blood or lymphatic vessel linings only, de-
pending on what specific co-receptors the tumor cells express.
It has also been suggested that the choice between
lymphangiogenesis and angiogenesis may depend on the ratio
of the different inducing factors present within the local tumor
microenvironment [82]. Also, crosstalk between lymphatic
and blood endothelial cells, as well as between endothelial
cells and the vessel milieu, should not be ignored as important
aspects in the selection of one of the two routes of tumor cell
dissemination [80]. It appears that the ultimate selection de-
pends on several factors, including the specific structure and
mechanical functionality of the vessels as also the expression
of adhesion molecules, the secretion of chemokines and the
activity of specific signaling pathways. Which pathway is
chosen depends on the concentration of local factors at the
primary site as also at the site of the metastatic niche, the
tumor cell of origin, the stage of tumor development and,
conceivably, the patient’s health status. It seemsmost probable
that both routes may be involved in metastasis, but not neces-
sarily at the same time (Fig. 1).
7 Are lymphatic vessels developed
during metastasis?
For a long time scientists were convinced that only blood
vessels, which drain the whole body, are able to transport
cancer cells to secondary, metastatic sites. This view changed
when direct and indirect paracrine tumor-stroma interactions
in the primary tumor niche, as well as intra-nodal
lymphangiogenesis, were discovered [83]. It was found that
tumor cells can alter the surrounding microenvironment and,
thus, influence tumorigenesis through crosstalk with dendritic
cells, CAFs, macrophages, lymphocytes and pericytes, all of
which can secrete soluble molecules that exhibit angiogenic or
lymphangiogenic activities [84]. These molecules may, in
turn, stimulate the enlargement of tumor lymphatic vessels,
thereby facilitating cancer cell invasion. Another milestone
was the introduction of the lymphvascular niche concept
[85]. This concept may explain the role of lymphatic
vessel formation within nodes, thereby constituting an
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intermediate platform for the lymphatic metastasis of cancer
cells. Indeed, it has experimentally been shown that primary
tumors can induce lymphatic vessel formation (neo-
lymphangiogenesis) within the tumor draining lymph node
[86]. This process precedes metastasis, possibly indicating
that primary tumors may first generate a favorable microenvi-
ronment at this site for a subsequent preferential and success-
ful dissemination. This lymphvascular niche may not only
attract spreading tumor cells but also a subset of cancer stem
cells (CSCs), which are the potential initiators of secondary
tumor development at distant sites [87–89]. This notion is also
of relevance for clinicians who use resected primary tumor
samples and regional lymph nodes to determine the stage of
the disease, the most optimal treatment regimen and the pa-
tient’s prognosis.
8What is the role of lymphatic and blood endothelial
cells in metastasis?
Another important point is the origin of the endothelial cells
that form tumor lymphatic vessels. As yet, three potential
sources of lymphatic endothelial cells (LECs, Fig. 2) have
been reported [87]. The first one is a pre-existing lymphatic
vessel in which, after appropriate stimulation, LECs prolifer-
ate and migrate leading to neo-lymphatic outgrowth.
Subsequently, the tumor cells and the tumor stroma induce
the formation of new lymphatic capillaries by secreting
VEGF-C and other cytokines and chemokines. Subsequent
interactions with specific receptors induce LEC-based tube
formation by stimulating cell proliferation and longitudinal
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Fig. 1 Routes of cancer cell spread. Metastatic cells may enter directly
into blood vessels (hematogenous spread) that vascularize the tumor mass
and, in this way, disseminate to distant sites. Another trail of cancer cell
spread may be the penetration into lymphatic vessels (lymphogenous
spread) and dissemination via the lymph flow to sentinel and,
subsequently, distant lymph nodes. Next, the cells may enter the














Fig. 2 Origin of lymphatic endothelial cells. Endothelial cells that form
neo-lymphatic vessels may originate from three alternative sources. First,
they may originate from pre-existing lymphatic vessels in which
lymphatic endothelial cells (LECs) proliferate and migrate, resulting in
outgrowths that vascularize the tumor mass. Second, they may originate
from pre-existing blood vessels in which blood endothelial cells (BECs),
through the action of lymphatic growth factors, trans-differentiate into
lymphatic endothelial cells. Third, they may originate from progenitor
bone marrow-derived cells that, after recruitment to sites of
lymphangiogenesis, in the presence of specific growth factors undergo
trans-differentiation into lymphatic endothelial cells
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derived from local vessels in specialized parts of the lymphatic
system [87, 90]. A second route for the formation of tumor
LECs is the transdifferentiation of endothelial cells from pre-
existing blood vessels. In this process VEGF-C plays an es-
sential role, as also the lymphatic-specific receptor VEGFR-3,
which is expressed in blood vessels in tumors, and the key
transcription factors SOX18, COUP-TFII and PROX-1 [87,
90, 91]. Likewise, it has been shown that integration of circu-
lating cells that exhibit lymphendothelial features may initiate
a pathologic outgrowth of the lymphatic system. Thus, a third
source of tumor LECs comes from transdifferentiation of non-
endothelial cells [92]. Although bone marrow-derived cells
(BMDCs), including endothelial progenitor cells, are essential
for the formation of new blood vessels, it is conceivable that
theymay also contribute to neo-lymphangiogenesis in tumors.
The i r par t i c ipa t ion may not only be d i rec t v ia
transdifferentiation, but they may also play inducing or
supporting roles under pathological conditions, without nec-
essarily taking part in the lymphangiogenic process itself [93].
Other cells, such as mesenchymal stem cells (MSCs) or tumor
associated macrophages (TAMs), may also participate in this
process. Under specific conditions prevailing in tumor masses
such as hypoxia, MSCs may differentiate into ECs, thereby
contributing not only to angiogenesis but also to
lymphangiogenesis [94]. TAMs, which belong to the myeloid
lineage, are multifunctional cells that, depending on the
micro-environmental conditions, may switch their phenotype
and functionality. They can transdifferentiate and structurally
act as ECs, i.e., form cellular elements of the lymphatic vessel
wall [95]. On the other hand, macrophages also constitute a rich
source of bioactive molecules that, under appropriate condi-
tions such as tumor inflammation, can be released by the acti-
vated cells. Among these molecules are VEGF-A/-C/-D, which
initiate lymphangiogenesis both through the stimulation of
LEC proliferation and the consecutive recruitment of TAMs.
In this latter scenario, it is highly probable that both subtypes of
macrophages (i.e., M1 and M2) may interact with tumor LECs
and participate in pathologic lymphangiogenesis, either directly
or indirectly in a paracrine fashion [87, 96–100].
In blood vessels, a similar role is played by blood endothe-
lial cells (BECs). Both BECs and LECs are endothelial cells,
so it may be reasonable to assume that these two types of cells
do not differ significantly. In conformity with the diverse roles
played by these cells in blood and lymphatic vessels, however,
they exhibit clear differences in cell-cell and cell-matrix inter-
actions. In fact, differences have been found not only in their
arrangements in the respective vessels, but also in their re-
sponses to the micro-environmental signals that they receive
and secrete (i.e., angiocrine and lymphangiocrine factors).
These functional differences may obviously result from the
interstitial flow conditions to which the ECs are exposed,
but it has also recently been shown that an important role is
played by the genes they express [101–104]. This is a third
level at which the morphological features and the micro-
environmental interactions of ECs may be programmed and
controlled. Despite these differences, both BECs and LECs
play important roles in blood and lymph flow and, under path-
ologic conditions, they may serve as enhancers of tumor cell
adhesion to the vessel wall, the transmigration of tumor cells
and, consequently, tumor progression.
9 Do intra- and peri-tumor lymphatic vessels
participate in tumor cell dissemination?
Another intriguing question is to what extent intra-tumor lym-
phatic vessels (ITLs) and peri-tumor lymphatic vessels (PTLs)
participate in tumor cell dissemination. Two types of tumor
lymphatic vessels can be distinguished on basis of their local-
ization in the cancerous mass. Lymphatic vessels, both pre-
existing and newly formed, can be found in the tumor periph-
ery and inside the tumor mass and are, accordingly, called
peri- and intra-tumoral lymphatic vessels, respectively [105].
Although their roles in tumor dissemination are different, they
are both considered to be responsible for the formation of
metastases. ITLs have been associated with a poor survival,
whereas PTLs have been associated with the occurrence of
nodal metastases and overall clinical outcome [106–108]. In
primary colorectal tumors, immunohistochemical staining has
revealed the presence of an extensive PTL network, which
may be related to a relatively short time from tumor develop-
ment to the formation of metastases [107]. PTLs are generally
believed to uptake tumor cells and to facilitate their dissemi-
nation. ITLs are, on the other hand, usually small, com-
pressed, collapsed and non-functional, due to increased me-
chanical forces related to tumor growth, the invasion of mi-
grating tumor cells and an increased interstitial fluid pressure
inside the tumor mass [87]. Therefore, ITLs may be consid-
ered as components within tumors that initiate and promote
metastasis, but do not act as routes of direct cancer cell spread
or enhanced lymph node metastasis (LNM). This role is at-
tributed to PTLs, which surround the tumor periphery with
functional vessels. By increasing the absorptive area, which
collects fluid and tumor cells from the external layers of the
cancer mass that mainly contain fast proliferating tumor cells,
they promote lymphatic metastasis [109]. Such lymphatic ves-
sels are sufficient for a cancer to spread, which is supported by
the fact that tumors that lack ITLs are often still able to dis-
seminate. Therefore, an increased PTL vessel density, espe-
cially in VEGF-C over-expressing tumors, is usually consid-
ered as a predictor of a high risk of lymphatic metastasis [110].
Additionally, when tumor cells penetrate PTLs they may,
through direct interaction, stimulate the proliferation of nor-
mal LECs (NLECs) and, in this way, promote or enhance
lymphangiogenesis. Obviously, paracrine influences of
NLEC-derived lymphangiogenic factors are also important.
Vessels in metastasis 403
Together, these factors may be potent enough to re-program
NLECs to tumor LECs (TLECs), which exhibit different mor-
phological, functional and molecular characteristics [1].
10 Additional factors influencing tumor cell
dissemination
Many additional factors are known to be strongly related to
tumor cell dissemination and, consequently, a poor prognosis,
including lymphatic vessel density (LVD), blood vessel den-
sity (BVD), interstitial fluid pressure (IFP) and tumor hypox-
ia. Although these factors are not unique to tumor dissemina-
tion and/or a poor prognosis, they may occasionally constitute
a therapeutic problem.
10.1 Lymphatic vessel density and blood vessel density
Lymphatic vessel density (LVD) is defined by the number of
ITLs and PTLs per area. A high LVD may facilitate direct
interactions between tumor cells and lymphatic vessels, there-
by increasing the probability of invasion. In many tumors, a
correlation has been found between a high LVD and the oc-
currence of lymph node metastases. Moreover, it has been
found that in colonic carcinomas the number of tumor-
associated lymphatic vessels may be increased compared to
that in the normal tissue microenvironment [7, 111]. Such
features predict an unfavorable prognosis [108]. However, it
is still unclear whether a high LVD is a condition sine qua non
for metastasis, or whether it only initiates and facilitates the
spread of tumor cells. Another point that requires clarification
is whether quantification of lymphangiogenesis can be used as
a diagnostic criterion for early and late tumor stages. In addi-
tion, it should be established whether imaging of lymphatic
vessels is sensitive enough to be used as a diagnostic and
prognostic tool in cancer patients. Some studies support the
usefulness of this approach, claiming that a high lymphatic
micro-vessel density, but not the invasion of tumor cells into
lymphatic vessels, may be considered as a biomarker that
correlates with a poor clinical outcome [112–115]. The out-
come of these approaches may, however, depend on the con-
ditions and the assumptions made for the clinical tests.
Therefore, in occasional tumors a low lymphatic micro-
vessel density may be related to a high invasive capacity of
the tumor cells and, as a consequence, an early dissemination.
Clearly, further research is needed to validate either one of
these hypotheses.
Blood vessel density (BVD) provides a measure of blood
vessel development and remodeling in both the tumor micro-
environment and the tumor mass itself [116]. BVD results
from the activity of pro- and anti-angiogenic factors. It has
been shown that besides VEGF, also other factors may affect
blood micro-vessel expansion. The placental growth factor
(PLGF) has for example been reported to affect cervical can-
cer BVD and, concomitantly, its progression and metastasis.
Alternatively, PLGFmRNA expression has been found to also
correlate with LVD [117]. Above (section 3) we noted that
abnormal tumor blood vessel structures may be indicative of
an ongoing metastatic process. The impact of BVD on the rate
of tumor cell dissemination could, however, also be consid-
ered as a predictor of metastasis, similar to LVD. It has already
been shown that LVD in conjunction with BVD may serve as
an independent prognostic factor in colorectal carcinoma
[118]. In general, it is likely that higher BVDs and higher
LVDs will correlate with each other and with a higher proba-
bility of the formation of distant metastases. However, all
these features may be related to the cancer type, as well as to
the way the vessels are formed and the functional and struc-
tural characteristics of the newly formed vessels. With the
current state of knowledge, the exact mechanisms underlying
anomalous tumor vascularization, i.e., lymphangiogenesis or
angiogenesis, remain to be resolved.
10.2 Interstitial fluid pressure
It is well known that an abnormal blood or lymphatic vascu-
lature, or in some cases the lack of a lymphatic system, may
lead to an increase in interstitial fluid pressure (IFP) [119,
120]. Impaired lymph drainage and increased lymphatic per-
meability are the main factors that result in IFP alterations.
Maximum IFP values have been observed in cases with a high
micro-vascular density (MVD) due to a concomitant hetero-
geneity of the tumor vasculature and an uneven distribution of
the vessels within solid tumors [119]. An elevated IFP is a
barrier to tumor therapy, since it impairs the access of anti-
tumor agents to the tumor mass and facilitates the entrance of
transformed cells into the peripheral lymphatic vessels. This
implies that tumors may be treated by reducing the MVD and,
thereby, lowering the IFP [119, 121]. An elevated IFP may
increase the number of dying cells within the tumor mass and
induce the formation of abnormal blood and lymph vessels,
due to over-expression of VEGF. This may, ultimately, result
in increased tumor cell motility [96]. Based on this, IFP has
been proposed as a potential biomarker for metastatic spread
[122]. There are, however, also data indicating that high pri-
mary tumor IFP values may not correlate with a high metasta-
tic rate. It has also been suggested that tumor IFP values may
serve as biomarkers for treatment responses, rather than being
the cause of metastasis [121].
10.3 Tumor hypoxia
Another important causative factor and indicator of tumor
dissemination is low oxygen tension (hypoxia). The effects
of hypoxia are controlled by the activity of the transcription
factor HIF-1 [123, 124]. HIF-1 is a heterodimer consisting of
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two subunits: a constitutively expressed β subunit and an
oxygen-regulated α subunit. In colorectal cancer a significant
correlation between VEGF-C and HIF-1α expression has
been observed. The clinic-pathological consequences of this
relation include lymphatic capillary formation and lymphatic
liver metastasis [125, 126]. HIF-1 regulates the transcription
of more than 70 genes, including those enhancing cellular
metabolism and initiating angiogenesis and metastasis. HIF-
1 inhibition prevents tumor initiation, progression and spread
to distant organs via lymph and blood vessels, and limits re-
sistance to therapy [127]. A special role in VEGF-C/HIF-1α
interdependency is played by inflammation and by the accu-
mulation and activity of TAMs in hypoxic areas. In response
to a decreased oxygen tension and an inflammatory microen-
vironment, HIF-1α expression may become up-regulated in
macrophages. This up-regulation enhances the expression of
VEGF-A/-C which, in turn, induces LEC differentiation and
proliferation. As a result, new lymphatic vessels are formed
and pre-existing lymphatic vessels are re-modeled, thereby
creating an opportunity for tumor cells to invade [125, 128,
129]. Similarly, HIF-1 has been found to act as a strong pro-
angiogenic factor. It stimulates BEC proliferation, which con-
tributes to the formation of new blood vessels [116]. On the
other hand, it has been shown that decreased HIF-1α expres-
sion, due to up-regulation of a basic helix-loop-helix (bHLH)
transcriptional repressor (SHARP1, bHLHE41 or DEC2),
may inhibit tumor growth and angiogenesis via a negative
regulation of VEGF expression [130].
Continuous re-modeling of blood vessels is the main rea-
son for an unstable blood flow, which may induce cyclic hyp-
oxias. HIF-1, which is induced by a low oxygen tension (be-
low 1%), stimulates glycolysis, angiogenesis, drug resistance,
autophagy, proliferation of tumor cells and immunosuppres-
sion, as well as tumor cell motility. It appears that increased
LVD, BVD and IFP in the primary tumor niche are all closely
related to the induction of tumor hypoxia and should, there-
fore, all be considered as components of a metastasis-
supporting microenvironment.
11 Regional lymph node metastasis
Dissemination of cancer cells to regional lymph nodes is the
first step in metastasis and, as such, serves as a useful tool for
cancer staging and prognosis [131, 132]. In general, lymph
node metastasis correlates with a poor prognosis. Other, aux-
iliary factors that predict a poor outcome include micro-
lymphatic vessel density (MLD) and high expression levels
of VEGF-C, CXCR4, Flt-4, VEGFR-3 and VEGF-D, which
have been proven to contribute to lymphatic involvement and
nodal metastasis [133–136]. Factors that regulate or alter the
rate of lymphatic metastasis can be classified as endocrine,
cytotoxic, anti-angiogenic, anti-inflammatory and immune
modulatory. At a higher level, these factors can be divided
into exogenous and endogenous, influencing stimulators or
inhibitors of lymph node dissemination [103].Whether lymph
node metastases indeed fully correlate with a poor prognosis
and whether they may constitute a prognostic value in
predicting distant dissemination of tumor cells to other organs
is still a matter of debate. On the one hand, it has been stated
that lymph node metastasis may not be related to tumor ag-
gressiveness and tumor cell migration to distant organs. This
claim is based on two observations. Firstly, it has been found
that lymphadenectomy may not provide survival benefits and
that tumor cells from primary masses may exhibit a similar
disseminating potential as those from lymph nodes. Secondly,
it has been found that tumor cells that have entered and
adapted to the lymphatic system may not be able to efficiently
form organ-specific metastases [137]. An opposing view is
that disseminating tumor cells may efficiently use lymph node
blood vessels or efferent lymphatic vessels to spread to other
parts of the body. In addition, dissemination to lymph nodes
may also occur in the absence of typical lymphangiogenesis,
since cancer cells may also employ pre-existing lymphatic
vessels. Therefore, while the presence or absence of cancer-
related lymphangiogenesis may depend on tumor type, migra-
tion into lymph nodes seems to be an indispensable element of
effective metastasis [138]. The latter theories appear to closely
reflect the actual situation, since a lack of nodes often means
that no distant metastases can be formed, which indicates that
transition of tumor cells via nodes is a prerequisite for further
dissemination. Lymphangiogenesis and migration of tumor
cells into lymph nodes seems to be a preferential, active pro-
cess that is necessary for further dissemination. Tumor cell
migration may also induce lymph node lymphangiogenesis
(LNL). The concept of LNL suggests that lymphatic and dis-
tant metastases are closely connected with each other as well
as with tumor-inherent behavior and local responses of the
host immune system to tumor-derived stimuli [139].
12 The primo vascular system as a possible conduit
for metastatic cells
The primo vascular system (PVS) is a recently discovered
novel circulatory system that may exist next to the lymphatic
and blood vascular systems. Initially, vasculogenic mimicry
was considered to represent an additional relevant vascular
structure, but its primitive micro-circulation failed to provide
an explanation for potential routes of tumor cell metastasis.
Therefore, additional studies were performed that finally led
to the discovery of a third vascular compartment currently
known as the primo vascular system [140–142]. This system
was found to be present throughout the whole body on organ
surfaces, inside lymphatic and blood vessels and their sub-
vessels, as well as on the surface, around and within
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subcutaneous tumors [140, 141, 143, 144]. This structure is
anatomically composed of small primo vessels (PV) with di-
ameters of 20–50 μm and primo nodes (PN) approximately
100–1000 μm in size [141, 143]. Because of its wide distri-
bution, its high density in tumor masses and its connection
with the tumor microenvironment, the PVS is currently con-
sidered as a potent route for cancer cell metastasis. Its role may
be important especially since the PVS directly connects pri-
mary and secondary tumors and since cancer cells can actively
be transported via this system [143]. Moreover, because
the PVS has its own circulating fluid, which contains cells
expressing stem cell markers (i.e., CD133, Oct4 or Nanog),
it may play a role in the regeneration of cancer stem cells or
serve as a unique niche for these cells [140, 143]. It may,
therefore, be hypothesized that next to lymphatic and
blood vessels, cancer cells use the PVS for effective dis-
semination and the formation of secondary tumors at dis-
tant sites. This hypothesis may at least partially explain the
failure or ineffectiveness of previous and current clinical
trials designed to inhibit metastasis by only suppressing
lymphangiogenesis or angiogenesis [144]. It would also
disprove the dogma of the existence of only two routes
for cancer cell dissemination.
13 Conclusions and future perspectives
Both in vivo animal models and in vitro wound healing assays
have indicated that lymphangiogenesis occurs after angiogen-
esis [91, 145]. The formation of lymphatic vessels may, there-
fore, rely not only on lymphangiogenic but also angiogenic
factors. The induction of lymphangiogenesis may also be af-
fected by micro-environmental conditions at the primary tu-
mor site, including typical physical or mechanical stresses.
When angiogenesis occurs, the number of proliferating tumor
cells within the solid tumor mass should be large enough to be
able to mechanically expand the primary niche. In addition to
that, lymphatic vessel formation may be induced/regulated by
the hydrostatic pressure related to the newly formed and
still leaky vessels. Although tumor lymphangiogenesis is
considered to be secondary to angiogenesis, it may also
occur independent from the formation of new blood ves-
sels. Currently, it is believed that both systems play an
equally vital role in tumor spread. This notion is substan-
tiated by the fact that lymphatic and blood vessels are
physically connected, and that tumor cells can enter the
blood stream directly via venous capillaries or indirectly
via lymphatic vessels.
Knowledge gained on the mechanisms of cancer metastasis
should be transferred to clinical practice. One area of clinical
application is based on the awareness that tumor spread de-
pends on the production and availability of specific factors. It
is now common knowledge that malignant carcinomas spread
to distant organs via routes that the organism uses to supply its
tissues with oxygen and nutrients. To survive and migrate to
distant sites, cells within the tumor mass have to develop
mechanisms that enable them to create connections with nor-
mal arteries in the surrounding tissues. The initiation of blood
and lymphatic vessel formation in tumors is associated with
the activation of specific paracrine factors present within the
microenvironment. These factors are produced both by the
tumor cells themselves and by their surrounding stroma.
This knowledge is currently employed in therapeutic models
that involve the specific blocking of selected molecules (i.e.,
cytokines, chemokines and growth factors) produced in ab-
normal quantities in cases with, or at the risk of developing,
metastases. Also, targeted immunotherapy studies are current-
ly aimed at blocking the formation of pathways of tumor cell
spread. Another aspect of metastasis both via blood and lym-
phatic vessels that is important from a clinical point of view is
related to the fact that disseminating tumor cells and tumor
cells at distant sites may acquire resistance to chemotherapy,
radiotherapy and apoptosis-inducing therapy. Knowledge on
the mechanisms underlying the acquisition of these resis-
tances can be used for the design of new clinical management
strategies aimed at overcoming or preventing the development
of these resistances.
In the future, the knowledge gained on the mechanisms
underlying lymphangiogenesis and angiogenesis should not
only allow a more effective treatment of cancer patients
through e.g. the inhibition of metastasis, but should also give
clinicians more effective tools for the prevention and progno-
sis of cancers based on the degree of tumor-associated vascu-
lature development. The future clinical management of
patients based on knowledge of tumor spread mechanisms
may more profoundly rely on subtle interventions within
the molecular pathways regulating lymphangiogenesis
and angiogenesis, as well as the molecular pathways reg-
ulating tumor cell motility. As there is currently no ex-
plicit evidence available that one system is more efficient
in cancer cell dissemination than the other, further re-
search is needed to determine the exact role of both blood
and lymph vessels in the development and metastasis of
tumors of different origin.
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